Silkis/Vectical

Analyst Outlook

Silkis/Vectical’s (calcitriol; Horizon Pharma/Galderma) more favorable side-effect profile compared to

calcipotriol-based vitamin D brands Dovobet (calcipotriol/betamethasone; Leo Pharma/Kyowa Hakko

Kirin) and Dovonex (calcipotriol; Leo Pharma), alongside the fact that it contains a naturally occurring

vitamin D derivative, boosts its clinical attractiveness; however, dermatologists are unconvinced by its

efficacy. Indeed, interviewed key opinion leaders indicate their limited usage of Silkis/Vectical,

highlighting that they do not see any advantages in prescribing it over the calcipotriol-based

products.

Drug Overview

Silkis/Vectical contains the active ingredient calcitriol, a biologically active form of vitamin D3.

Silkis/Vectical is available as a topical ointment, which reduces excessive skin cell production and

helps to improve the symptoms of psoriasis. It is sold under the brand name Silkis in Europe and was

launched in the US as Vectical in February 2009, following its approval by the US Food and Drug

Administration for the treatment of mild to moderate plaque psoriasis in adults aged 18 years and

older (Galderma, 2009).